TFAP2C and breast cancer: It is found that mRNA levels of TFAP2C, a transcription factor expressed in BC, correlated with the protein expression levels and high transcript and protein levels correlated with decreased response to fulvestrant treatment.37 Interestingly, primary tumors from a subset of patients enrolled in the CONFIRM trial were evaluated in the transCONFIRM study in order to recognize a gene signature of response to fulvestrant in advanced BC.